BOSTON, Sept. 28, 2018 /PRNewswire/ -- SeLux Diagnostics, Inc., which is leading a new era in personalized medicine to treat multi-drug resistant organism infections and combat antibiotic resistance, today announced it has signed a milestone-based contract worth up to $45 million, if all contract options are exercised (base award is for $9.3 million), with the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services' (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR).
SeLux immediately receives $9.3 million from BARDA to fund the clinical trial necessary for SeLux NGP, SeLux's next-generation phenotyping platform. The additional $36 million will fund the development of SeLux's second-generation rapid sepsis diagnostic system.
SeLux NGP is a breakthrough in personalized medicine that will enable infectious disease physicians to prescribe targeted antibiotic therapies up to 3 days faster than possible with current technologies. This advance offers the promise of improving patient care while simultaneously limiting the medical overreliance on broad-spectrum antibiotics, which fuels the current antibiotic resistance epidemic.
"We are very grateful to receive this support and to partner with BARDA to improve infectious disease patient care by developing tools that help physicians make earlier, better-informed decisions," said Steve Lufkin, CEO of SeLux Diagnostics. "The rise in drug-resistant bacteria in the past decade is driving an urgent need for innovative diagnostics that can transform the treatment of infectious diseases. SeLux NGP will not only save patient lives but will dramatically decrease the overuse of broad-spectrum antibiotics and contribute to greater Antibiotic Stewardship worldwide."
The SeLux NGP Platform
SeLux NGP determines targeted antibiotic therapies faster and more precisely than possible with today's state-of-the-art techniques. The proprietary Selux technology uniquely provides results 2-5 times faster and for 3-4 times the number of antibiotics than current systems can. Uniquely amongst competitors, SeLux NGP provides the high-throughput, low-cost testing demanded by clinical microbiology laboratories and integrated healthcare systems.
About SeLux Diagnostics
SeLux Diagnostics is transforming patient care by offering a breakthrough in rapid, comprehensive, accurate antimicrobial susceptibility testing (AST) so that hospitals and health systems can better treat patients with infectious disease, including those infected with multi-drug resistant organisms. By speeding the reporting of AST results, SeLux enables providers to simultaneously improve patient outcomes, reduce patient lengths-of-stay and pharmacy costs, and address the growing antibiotic resistance epidemic by contributing to greater Antibiotic Stewardship worldwide. The 4-year-old company is based on the opposite side of Boston, MA from where it originated in a co-founder's attic. Learn more at www.seluxdx.com.
CONTACT: Jay Staunton, 1-781-790-6023, [email protected]
SOURCE SeLux Diagnostics, Inc.